Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.
about
Targeting Cell Survival Proteins for Cancer Cell DeathTargeted Therapies in Adult B-Cell MalignanciesThe role of BH3-mimetic drugs in the treatment of pediatric hepatoblastomaFrom modules to medicine: How modular domains and their associated networks can enable personalized medicineTargeting BCL2-Proteins for the Treatment of Solid TumoursTargeting the Bcl-2 family for cancer therapyTargeting Mcl-1 for the therapy of cancerPan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cellsNavitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancerPPIMpred: a web server for high-throughput screening of small molecules targeting protein-protein interaction.Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapyRole of the axonal initial segment in psychiatric disorders: function, dysfunction, and interventionA multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.Novel therapeutics for aggressive non-Hodgkin's lymphoma.Obatoclax regulates the proliferation and fusion of osteoclast precursors through the inhibition of ERK activation by RANKLAssessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerCombined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review.An evidence-based review of obatoclax mesylate in the treatment of hematological malignanciesObatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivoYeast techniques for modeling drugs targeting Bcl-2 and caspase family members.Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cellsHistone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.Through a glass less darkly: apoptosis and the germinal center response to antigen.Apoptosis-modulating drugs for improved cancer therapy.A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia.Manipulating the apoptotic pathway: potential therapeutics for cancer patients.Small molecules as pro-apoptotic anticancer agents.Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?Oncogenic protein interfaces: small molecules, big challenges.Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.Targeting cancer cell mitochondria as a therapeutic approach: recent updates.Major apoptotic mechanisms and genes involved in apoptosis.
P2860
Q26765447-03D2D9CA-4218-471C-9FDF-E74E78043BF1Q26783195-4466606D-5E05-4132-BB88-0D7CA5548029Q26827928-1648472D-30E2-4F1F-A013-3DFCCCE472F7Q26830811-BDA66E07-F8E0-4A2D-ACA0-83267693681EQ26853686-A8E0FD13-A04B-4DD4-9A75-5EA5902F967FQ26866936-6B182453-6510-473F-B17B-EB0BE2C1139FQ27011870-094BB28E-52AC-4691-A4D3-46EAD884F4F8Q28542827-AE3E1990-378A-424A-9B62-F6E98CEDF4E8Q33392920-728A4977-0F08-4E96-9847-E7F1CA47AE53Q33395544-55ECC6F0-BCB5-47AF-AE9B-B24F1D43DA05Q33630135-A8A43CFE-2EB2-4EC9-B358-912E26928976Q33830911-72435B31-0D30-438C-9DFB-287F9A0594D7Q34004454-FF60CBF9-2523-4C32-BD9A-E47CD384A05BQ34071914-EF96E354-F981-44D4-BA41-38B0BA0481AFQ34294097-AB7E19A0-9F44-496A-A217-23B0A2817E88Q35007971-1DFCEB04-E995-43A2-AAA2-B227A4FD9DCEQ35111768-5F8918C6-C8CF-4552-993B-7019CB99641CQ35188522-9E9E5FC7-5B84-4BDC-B599-7BD5B225883DQ35212727-0E7A07B6-B19C-4FB7-A5BD-E3DBEF5CC5F0Q35835203-BD2C3E1D-BD84-4476-8306-BC91B29CD789Q35987399-BC169C8E-A228-4F02-8C68-3AADD1948725Q36337960-E106B683-8ACE-4D51-B630-EF25A8FD6665Q36541458-B5A094D7-952F-494F-80E9-090073BC95D4Q36696524-04A808BB-0B9A-44FC-A560-F5A5C09D8007Q36697045-478A1D8F-E6E1-486F-BD5A-5AC5F1F5082DQ36907080-25251CA6-45C6-4C1C-A72B-39B1DFF4A400Q37046690-7DBE0839-C40F-46A3-8EE7-A952C37149C5Q37589245-438A3D43-49BA-4D99-899D-C31713882D1FQ37680565-1F5AECDE-CFAA-4EC7-8250-FBBB1626DB32Q37983083-08248ACA-8441-41A3-9682-E2593B4B8E13Q38002487-6C28FE06-760E-447A-8027-605FAB4BAA5CQ38005914-0F6C1D8E-22F4-4464-92B9-2E91E99D78A0Q38061861-7CC107CA-3057-4C99-BB17-F2CFB114CA54Q38115574-BB68260B-B699-4F56-BEB0-AE1BD7711CDDQ38162939-C740D7D0-39B2-43FD-BE2E-2CA910046FC8Q38193997-FE3601B2-3D76-4333-974A-3B899C30A920Q38195457-D8F393E8-5455-412A-B655-EA4B519C9101Q38442515-4C3C81F2-43DF-4604-A9DC-684000FFC255Q38668524-E72E8B32-6EE3-4901-A35D-123C6085F93EQ38802454-EC3F2FFE-2E2A-4593-9565-D1C4AE6AB892
P2860
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Phase I dose finding studies o ...... nced solid tumors or lymphoma.
@en
type
label
Phase I dose finding studies o ...... nced solid tumors or lymphoma.
@en
prefLabel
Phase I dose finding studies o ...... nced solid tumors or lymphoma.
@en
P2093
P2860
P1476
Phase I dose finding studies o ...... nced solid tumors or lymphoma.
@en
P2093
David Mendelson
J F Deeken
Jean Viallet
Jimmy J Hwang
John Kuruvilla
John L Marshall
Lillian L Siu
Mark S Berger
Michael J Pishvaian
P2860
P304
P356
10.1158/1078-0432.CCR-10-0822
P407
P577
2010-06-10T00:00:00Z